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Abstract		
Introduction:	 The	 gastrointestinal	 microbiome	 is	 crucial	 for	 the	 development	 of	 a	 balanced	
immune	system.	Antibiotics	are	frequently	administered	to	infants	and	cause	intestinal	dysbiosis.	
This	narrative	review	highlights	the	long	term	health	consequences	of	antibiotic	administration	to	
infants	 and	 young	 children.	 The	 necessity	 of	 administration	 of	 antibiotics	 should	 be	 well	
considered,	 since	 an	 association	 with	 short	 term	 consequences	 such	 as	 antibiotic	 associated	
diarrhoea	 and	 long	 term	 adverse	 effects	 such	 as	 overweight,	 inflammatory	 bowel	 syndrome,	
allergic	disease		have	been	reported.				
Conclusion:	 	The	pros	and	cons	of	antibiotic	administration	to	infants	and	young	children	should	
be	considered.		
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Introduction 
The human gut microbiota has been estimated to be 
equal or probably even 10 to 100 times more 
important in number than the cells composing the 
human  body.1 Microbial colonization of the human 
gut begins in utero since bacteria have been 
detected in the umbilical cord, placenta, amniotic 
fluid and also in meconium.2 After birth, the 
gastrointestinal tract is colonized by a rapidly 
diversifying microbiota, and it is during the first 
years of life that the establishment of a stable gut 
microbiome occurs that will persist during later 
childhood and adulthood. Microbial colonization of 
the infant gastrointestinal tract begins immediately 
after birth, and is determined by many factors such 
as the maternal microbiota, delivery mode, feeding 
and medication such as antibiotics and proton 
pump inhibitors.1 Early colonization is crucial for a 
balanced development of the acquired immune 
system. In other words: early colonization is a 
major factor influencing for later health. It has been 
well established that antibiotics not only kill 
bacterial pathogens, but they will also profoundly 
disturb the equilibrium of the gastro-intestinal 
microbiome and are a well-known cause of 
dysbiosis. The use of antibiotics increased globally 
with 36% in a decade.3 The long-term 
consequences of gastro-intestinal dysbiosis during 
early life are the focus of this narrative review. 
There is a strong association between the 
microbiota composition and factors such as age, 
nutrition, stress, and many diseases and conditions 
such as allergy, diabetes, irritable bowel syndrome, 
overweight and inflammatory bowel disease. While 
much of the emerging literature has focused on the 
potential benefits of probiotic treatment, antibiotics 
used to treat pathogenic bacterial infections are 
known to disrupt the diversity and number of 
microbial organisms in the intestine. 
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Antibiotic associated diarrhea  
 
The most frequent and best studied consequence of 
intestinal dysbiosis as a consequence of antibiotic 
intake is antibiotic associated diarrhea (AAD). 
AAD is an immediate or short-term adverse effect 
of antibiotic treatment, occurs in +/- 20 % of all 
antibiotic courses and depends on the class of 
antibiotic, the presence of risk factors in patients 
(host factors, hospitalization, nosocomial 
outbreaks). AAD is defined as a change in stool 
frequency with at least three liquid stools/day 
occurring during two consecutive days (early onset) 
or two to six weeks after antibiotic treatment (late 
onset), and if no other cause can be identified 
(intercurrent viral or bacterial infection, laxative 
use, other cause).4 The class of antibiotics (broad 
spectrum), the duration of administration and the 
age of the patient are risk factors to develop AAD. 
The administration of some probiotic strains such 
as Lactobacillus rhamnosus and Saccharomyces 
boulardii CNCM I-745 reduce the incidence and 
severity of AAD.5 
 
Antibiotics early in life 
 
Antibiotics may have a much broader impact, 
especially if given perinatal or to young infants. 
The administration of antibiotics intrapartum both 
during caesarean and vaginal delivery are 
associated with infant gut microbiota dysbiosis.6 
Maternal intrapartum antibiotic treatment is a key 
regulator of the initial neonatal oral microbiome.7  
Maternal intrapartum antibiotic prophylaxis will 
have a significant impact on the infant faecal 
microbial population, particularly in that of 
breastfed infants.8 Intrapartum antibiotic 
administration results in a significant reduction in 
Bifidobacterium spp. strains.9 The reduced 
abundance of these beneficial microorganisms, 
together with the increased amount of potentially 
pathogenic bacteria, may suggest these infants are 
more exposed to gastrointestinal or generally health 
disorders later in age. Dysbiosis acquired perinatal 
or during early life will induce long term 
consequences. Maternal antibiotic treatment, 
administered  during pregnancy and lactation 
results in profound alterations in the composition of 
the microbiota in mothers and infants.10 Prenatal 
antibiotics are associated with a larger body mass 
index (BMI) at the age of two years.11 Children 
experiencing a higher number of respiratory tract 
infections in the first year of life already 
demonstrate an aberrant microbial developmental 
trajectory from the first month of life on.12 
Independent drivers of these aberrant 
developmental trajectories of respiratory 
microbiota members were mode of delivery, infant 
feeding, crowding, and recent antibiotic use .12 
Perinatal administration of antibiotics is often 
lifesaving and thus a medical need. However, 
special attention should be given to a balanced 
development of the gastrointestinal microbiome of 
infants born in these circumstances.   
 
Antibiotics and weight  
 
Subtherapeutic doses of antibiotics have been used 
as growth promoters in animal farming since the 
1950s .13 The effect is more pronounced for broad-
spectrum antibiotics, and it is attenuated when 
animals are raised in sanitary conditions. 
Burgeoning empirical evidence suggests that 
antibiotics also affect human growth. As early as 
1955, a randomized controlled trial in Navy recruits 
showed that a 7-week course of antibiotics led to 
significantly greater weight gain in the treated 
group compared with placebo.13 
Antibiotic exposure before 6 months of age 
or repeatedly during infancy, was associated with 
increased BMI in healthy children.14 Repeated 
exposure to antibiotics early in life, especially β-
lactam agents, was shown to be associated with 
increased weight.15 These adverse effects of 
antibiotics may play a role in the worldwide 
childhood obesity epidemic and highlight the 
importance of judicious use of antibiotics during 
infancy, favoring narrow-spectrum antibiotics.14 
Administration of three or more courses of 
antibiotics before children reach an age of two 
years is associated with an increased risk of early 
childhood obesity.16 In a cohort study, 6.4 % 
children were obese at four years of age and 
exposure to antibiotics was associated with an 
increased risk of obesity at four years.16 The more 
antibiotic courses, the stronger the risk.16 Children 
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receiving antibiotics in the first year of life are 
more likely to be overweight at 12 years of age 
compared with those who were unexposed (32.4 vs 
18.2%, P=0.002).17 Repeated exposure to broad-
spectrum antibiotics at ages 0 to 23 months is 
associated with early childhood obesity.15 Sixty-
nine percent of children were exposed to a mean of 
2.3 antibiotic courses before the age of 24 
months.18 Exposure to antibiotics during the first 12 
months of life was associated with a small increase 
in BMI in boys, but not in girls, aged 5-8 years in a 
large international cross-sectional survey .19 The 
intestinal microbiota of infants is predictive of later 
BMI and may serve as an early indicator of obesity 
risk. Bifidobacteria and streptococci, which are 
indicators of microbiota maturation in infants, are 
likely candidates for metabolic programming of 
infants, and their influence on BMI appears to 
depend on antibiotic use.20  If causality of obesity 
can be established in future studies, this will further 
highlight the need for restrictive antibiotic use.15  
Because common childhood infections were 
the most frequent diagnoses co-occurring with 
broad-spectrum antibiotic prescription, narrowing 
antibiotic selection is potentially a modifiable risk 
factor for childhood obesity.18 Administration early 
in life, cumulative exposure and broad spectrum 
antibiotics were additional risk factors associated 
with later obesity. In comparison to broad-spectrum 
antibiotics, narrow-spectrum antibiotics were not at 
any age or frequency associated with a risk for 
increased weight.18 However, some studies do 
report contradictory results. Exposure to antibiotics 
within the first 6 months of life compared with no 
exposure was also shown to be not associated with 
a statistically significant difference in weight gain 
through age seven years.21  
In summary, although literature is 
contradictory and thus the evidence is weak, there 
are many indicators that administration of broad 
spectrum antibiotics may be associated with a 
higher BMI during infancy and childhood.  
 
Antibiotics and immunity and allergy 
 
Synbiotic host and microbe interactions are critical 
for host metabolic and immune development. Early 
microbiota colonization may influence the 
occurrence of metabolic and immune diseases.1  
Maternal use of antibiotics before and 
during pregnancy was associated with an increased 
risk of cow's milk allergy in the offspring, and 
persisted after adjusting for putative confounders.22 
A clear association was found between three or 
more courses of antibiotics during early life and 
cow's milk allergy, non-milk food allergy and other 
allergies in a longitudinal data analysis of 30,060 
children.22 The associations became stronger for 
younger age and differed by antibiotic class.22 The 
risk of cow's milk allergy increased with increasing 
number of child's antibiotics used from birth to 
diagnosis of the allergy (test for trend P < 0.001).23 
  
Antibiotics and the respiratory tract 
 
Early introduction of solid foods such as fish and 
environmental factors such as living on a farm are 
protective factors for the development of later 
allergic disease. But administration of antibiotics 
during early life are a risk factor for allergic rhinitis 
and wheezing.  Antibiotics during the first year of 
life are associated with an increased risk for 
wheezing and asthma up to the age of three and six 
years, independent of lower respiratory tract 
infections during the first year of life.24-28 The 
strength of the association differs with the class of 
antibiotics, correlating with their effect on the 
gastrointestinal microbiome.24 A dose-response 
effect was observed: when five or more antibiotic 
courses were administered, the risk to develop 
asthma increased significantly (p<001). There is no 
association between antibiotic use and late-onset 
asthma.26  The adverse effect of antibiotics was 
particularly strong in children without a family 
history of asthma (P(interaction)=0.03).25 
Retrospective studies had the highest pooled risk 
estimate for asthma compared with database and 
prospective studies. Respiratory infections, later 
asthma onset (asthma at or after two years) and 
exposure to antibiotics during pregnancy are all 
independent risk factor. 
 
Antibiotics and Irritable Bowel Syndrome (IBS) 
 
A statistically significant link between early life 
infections and IBS in adults aside from bronchitis 
could not be demonstrated.29 These data confirm an 
early report concluding that antibiotic treatment 
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does not seem to be a major risk factor for recurrent 
abdominal pain at 12 years of age.30 However, 
antibiotic use during the neonatale period was 
reported to be associated with infantile colic.31  
 
Antibiotics and Inflammatory Bowel Disease 
(IBD) 
 
Exposure to antibiotics throughout childhood is 
associated with IBD, and this relationship 
decreased with increasing age of exposure to 
antibiotics. Exposure before one year of age had 
the highest risk, decreasing at five and 15 years, 
although even antibiotics at the age of 15 still 
indicated a significant risk factor to develop IBD.32 
Each antibiotic course increased the risk to develop 
IBD with 6% (4%–8%).32 Antibiotic use is 
common in childhood and its potential as an 
environmental risk factor for IBD warrants 
scrutiny.33 Antibiotic exposure was significantly 
associated with Crohn’s disease, being stronger in 
children, but was not significant for ulcerative 
colitis.34 However, the antibiotic courses may also 
be the consequence of unrecognized and 
undiagnosed symptoms of IBD. Therefore,  
causality cannot be confirmed since antibiotics may 
be prescribed to children with intestinal symptoms 
of as yet undiagnosed IBD.33 
 
Antibiotics and diabetes 
Exposure to a single antibiotic prescription was not 
associated with higher adjusted diabetes risk, 
whereas treatment with two to five antibiotic 
courses was associated with an increase in diabetic 
risk for penicillin, cephalosporins, macrolides and 
quinolones.35,36 The risk increased with the number 
of antibiotic courses. There was no association 
between exposure to anti-virals and anti-fungals 
and diabetes risk.35 Exposure to antibiotics is likely 
to increase type 2 diabetes risk, but not for type 1 
diabetes.36,37 However, the findings may also 
represent an increased demand for antibiotics from 
an increased rate of infections in patients with yet 
undiagnosed diabetes.36 
 
 
Conclusion 
 
The most prevalent childhood bacterial infections 
in primary healthcare are respiratory, 
gastrointestinal and urogenital infections. 
Antibiotics are often unavoidable and sometimes 
life-saving. In many developing countries, 
antibiotic dispensing and its use in medicine, cattle 
breeding and agriculture are inadequately 
regulated, or existing laws are not being 
appropriately implemented. In addition, human 
travel contributes to antimicrobial drug resistance 
around the world. All of these factors have led to a 
very high level of bacterial resistance. However, 
antibiotics also cause intestinal dysbiosis, which on 
its turn is associated with an increased risk for 
adverse outcomes such as AAD, IBS, IBD, allergy, 
overweight, etc. Prudent use of antibiotics is 
paramount not only to reduce the propagation of 
antibiotic-resistant organisms but also to minimize 
the potentially detrimental long-term metabolic 
consequences of early antibiotic exposure. The 
long term adverse effects of broad spectrum 
antibiotics should be considered before these drugs 
are administered to young infants. The 
administration of some specific probiotics strains 
such as Saccharomyces boulardii have been shown 
to reduce the risk of short term adverse effects of 
antibiotics such as the risk to develop AAD. 
Whether probiotics may also reduce the risk to 
develop long term adverse effects of intestinal 
dysbiosis associated with repetitive antibiotic 
administration has not been validated and should be 
a focus of future research. 
Future studies should investigate the effects 
of multiple exposures to broad-spectrum antibiotics 
during the second year of life. However, future 
studies should focus on the possible benefit of a 
rapid restoration of the dysbiosis caused by broad 
spectrum antibiotics. 
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Table 1. Antibiotics during early life and health effect.  
Reference Topic OR  95 % CI 
Metsälä 41 CMPA (AB mother before pregnany) 1.26 1.20-1.33 
 CMPA (AB mother during pregnancy) 1.21  1.14-1.28 
Scott 16 Obesity at 4 years 1.21 1.07-1.38 
 Obesity at 4 years (< 3 AB courses) 1.07  0.91-1.23 
 Obesity at 4 years (3-5 AB courses) 1.41  1.20-1.65 
 Obesity at 4 years (> 6 AB courses) 1.47  1.19-1.82 
Azad 17 Obesity risk in boys 5.35 1.94-14.72 
 Obesity risk in girls  1.13 0.46-2.81 
 Obesity risk in boys (9 years) 2.19 1.06-4.54 
 Obesity risk in girls (9 years) 1.20 0.53-2.70 
 Obesity risk in boys (12 years) 2.85 1.24-6.51 
 Obesity risk in girls (12 years) 1.59 0.68-3.68 
Bailey 18 Obesity (> 4 AB courses) 1.11 1.02-1.21 
 Obesity (broad spectrum AB) 1.16 1.06-1.29 
 Obesity (AB between 0-5 months) 1.11 1.03-1.19 
 Obesity (AB between 6-11 months) 1.09 1.04-1.14 
Hirsch 22 Milk allergy 1.78 1.28-2.48 
 Non-milk food allergy 1.65 1.27-2.14 
 Other allergies 3.07 2.72-3.46 
Risnes 25 Asthma (>6 years) 1.52 1.07, 2.16 
 Asthma (>3 years) 1.66  0.99, 2.79 
 Asthma (no LRTI < 1 year) 1.66  1.12, 3.46 
 Asthma (neg fam history) 1.89 1.00, 3.58 
 Pos allergy test 1.59  1.10, 2.28 
Ong 26 Transient wheezing  2.0 1.9-2.2 
 Asthma  1.6 1.5-1.7 
 Asthma (>5 AB courses) 1.9. 1.5-2.6. 
Alm 39 Allergic rhnitis 1.75  1.03, 2.97 
Metsälä 40 Asthma (AB mother) 1.31 1.21-1.42 
 Asthma (AB infant) 1.60 1.48-1.73 
Murk 42 Asthma (review, all studies) 1.52  1.30-1.77 
 Asthma (retrospective studies) 2.04 1.83-2.27 
 Asthma (database, prospective studies) 1.25  1.08-1.45 
 Asthma (adjusted for resp inf) 1.16 1.08-1.25 
 Asthma (onset> 2 years) 1.16 1.06-1.25 
 Asthma (AB during pregnancy) 1.24  1.02-1.50 
Pedersen 43 Otitis media (AB during pregnancy) 1.30 1.04-1.63 
 Otitis media (n° of AB courses) 1.20 1.04-1.40 
 Ventilation tubes (AB third trimester) 1.60 1.08-2.36 
Kronman 32 IBD  (AB < 1 year) 5.51  1.66-18.28 
 IBD (AB < 5 years) 2.62    1.61-4.25 
 IBD (AB < 15 years) 1.57  1.35-1.84 
 IBD (1 or 2 AB courses) 3.33  1.69-6.58 
 IBD (> 2 AB courses) 4.77  2.13-10.68 
Hviid 33 IBD 1.84 1.08 to 3.15 
 Crohn's disease 3.41 1.45-8.02 
 IBD (> 7 AB courses) 7.32 2.14-24.99 
Ungaro 34 Crohn’s disease 1.74 1.35-2.23 
 Ulcerative colitis  1.08 0.91-1.27 
 Chrohn’s disease (in children) 2.75 1.72-4.38 
 Crohn’s disease (metronidazole) 5.01 1.65-15.25 
 Crohn’s disease (fluoroquinolones  1.79 1.03-3.12 
Boursi 35 Diabetes (> 1 AB course, penicillin) 1.08  1.05-1.11 
 Diabetes (> 1 AB course, quinolones) 1.15  1.08-1.23 
 Diabetes (> 5 AB course, quinolones) 1.37  1.19-1.58 
AB: antibiotic; IBD: inflammatory bowel disease; n°: number; pos: positive; resp inf: respiratory infection 
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